Skip to main content
Top

Drugs

Issue 18/2021

Content (12 Articles)

Acknowledgement to Referees

  • Acknowledgement to Referees

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence

Shelley N. Facente, Angela M. Reiersen, Eric J. Lenze, David R. Boulware, Jeffrey D. Klausner

Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A

Nowell Solish, Jean Carruthers, Joely Kaufman, Roman G. Rubio, Todd M. Gross, Conor J. Gallagher

Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain

Mary-Ann Fitzcharles, Frank Petzke, Thomas R. Tölle, Winfried Häuser

Regdanvimab: First Approval

Yahiya Y. Syed

Correction to: Regdanvimab: First Approval

  • Correction

Yahiya Y. Syed

Tisotumab Vedotin: First Approval

Anthony Markham

Abrocitinib: First Approval

Emma D. Deeks, Sean Duggan

Penpulimab: First Approval

Sohita Dhillon

Keynote webinar | Spotlight on dry eye disease

  • Live
  • Webinar | 28-05-2026 | 13:00 (CEST)

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Watch it live: 28 May 2026, 13:00–14:00 (CEST)

Prof. Harminder Dua
Prof. Sajjad Ahmad
Prof. Anat Galor
Join the webinar
Webinar
Image Credits
Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images